36
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Lenalidomide
In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
Lenalidomide placebo
Capsules are identical to the active Lenalidomide capsules used.
Vacc-4X
Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
rhuGM-CSF
Granulocyte macrophage colony stimulating factor as a local adjuvant
EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin
Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1, Berlin
University Medical Center Hamburg-Eppendorf, Hamburg
Klinik I für Innere Medizin Klinikum Der Universität zu Köln, Cologne
Collaborators (1)
Bionor Immuno AS
INDUSTRY
Celgene Corporation
INDUSTRY